Erschienen in:
01.09.2012 | Case Report
Sunitinib and Thrombosis
verfasst von:
Gurpreet Lamba, Raveen Deol, Dhaval Shah, Ramandeep Sahni, Bharat Kumar Malhotra
Erschienen in:
Journal of Gastrointestinal Cancer
|
Sonderheft 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006 [
1]. Sunitinib inhibits cellular signaling by targeting multiple RTKs including platelet-derived growth factor and vascular endothelial growth factor receptors, which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets leads to reduced tumor vascularization, cancer cell death, and ultimately tumor shrinkage. This multi-targeted inhibition is also believed to be responsible for increased risk of arterial thromboembolism previously reported by Choueri and colleagues [
2]. We present the first case with both arterial and venous thrombosis in a patient treated with sunitinib. …